Key result
LANPs match dexrazoxane for doxorubicin cardioprotection in mice while lowering toxicity and boosting antitumor efficacy.
Why the study?
Doxorubicin therapy causes cardiotoxicity that limits its clinical use, and strategies to achieve concurrent cardioprotection and antitumor efficacy are needed.
Do LANPs reduce doxorubicin-induced cardiotoxicity and improve antitumor efficacy in female BALB/c mouse models?
Do LANPs reduce doxorubicin-induced cardiotoxicity and improve antitumor efficacy in female BALB/c mouse models?
LANPs represent a promising adjuvant strategy to mitigate doxorubicin-induced cardiotoxicity while enhancing antitumor efficacy in preclinical models.
May enable selective doxorubicin cardioprotection; leaves open human translation pending clinical trials.
. tumor tissues, achieving concurrent cardioprotection and antitumor sensitization during DOX therapy. In cardiomyocytes, LANPs degrade into the lipoic acid (LA)/dihydrolipoic acid (DHLA) pair, which exerts anti-oxidant activity to scavenge excessive ROS, thereby mitigating oxidative stress-associated pyroptosis and subsequent cardiac injury. In cancer cells with a relatively high reducing environment, LANP degradation predominantly yields DHLA, which promotes ROS accumulation, thereby enhancing pyroptosis-associated antitumor efficacy. In female BALB/c mouse models, LANPs afford cardioprotection comparable to dexrazoxane (DEX), the only clinically approved cardioprotective agent against DOX, while additionally alleviating systemic toxicity, particularly bone marrow suppression, an advantage not afforded by DEX. As expected, LANPs not only preserve but also potentiate DOX-induced antitumor efficacy. This study establishes LANPs as a promising adjuvant strategy for expanding the scope of chemotherapeutic applications beyond DOX.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied Doxorubicin-induced cardiotoxicity and cancer. Lipoic acid nanoparticles (LANPs) vs. Dexrazoxane (DEX) was evaluated on Cardioprotection, systemic toxicity, and antitumor efficacy. In female BALB/c mouse models, LANPs afforded cardioprotection comparable to dexrazoxane during doxorubicin therapy while alleviating systemic toxicity and potentiating antitumor efficacy.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: